HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples